MedPath

Medico-economic Evaluation Rehabilitation by Serious Games at Home for the Management of Patients With Parkinson's Disease Suffering From Gait and Balance Disorders

Not Applicable
Not yet recruiting
Conditions
Patients With Parkinson's Disease
Interventions
Device: play-based rehabilitaion
Registration Number
NCT04720365
Lead Sponsor
University Hospital, Rouen
Brief Summary

This is a multi-center, randomized, open-label, multi-center, randomized controlled study of 80 Parkinson's disease patients with gait and balance disorders in which 40 patients will be treated with serious games, in addition to their usual care, for 12 months and 40 patients will be treated with their usual care during this period. This study will be conducted in 4 centers, all of which are expert in the management of these patients.

After randomization, each patient in the "Intervention-Rehabilitation through Toap Run" group will have to complete 2 to 3 sessions per week at home with the serious game "TOAP RUN" using the Kinect® system for 1 year.

Detailed Description

This is a multi-center, randomized, open-label, multi-center, randomized controlled study of 80 Parkinson's disease patients with gait and balance disorders in which 40 patients will be treated with serious games, in addition to their usual care, for 12 months and 40 patients will be treated with their usual care during this period. This study will be conducted in 4 centers, all of which are expert in the management of these patients.

After randomization, each patient in the "Intervention-Rehabilitation through Toap Run" group will have to complete 2 to 3 sessions per week at home with the serious game "TOAP RUN" using the Kinect® system for 1 year.

The primary endpoint is a medical-economic endpoint: the difference in incremental cost-utility ratio at 12 months between the 2 groups of patients. Costs will be assessed at inclusion, at the end of 6 and 12 months. Secondary endpoints include clinical and neurophysiological assessments, focusing on gait and balance disorders, as well as cognition and emotional state. An imaging study for patients included in the Paris-ICM center is also planned to study the effects of serious game rehabilitation on brain function.

Patients in both groups will be free to use SG at the end of the intervention.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  1. Diagnosis of idiopathic Parkinson's disease (according to United Kingdom Parkinson's Disease Society Brain Bank [UKPDD] criteria) ;
  2. Age ≥ 18 years ;
  3. Patient with gait and/or balance disorders not improved by levodopa treatment with item 12 "walking and balance" ≥ 1 of the MDS-UPDRS (Movement-Disorders Society-Unified Parkinson's disease rating scale) part II, ON levodopa and/or item 13 of "gait freezing" ≥ 1 (Goetz, Tilley et al. 2008);
  4. Number of falls ≥ 2 in the previous year;
  5. Stable antiparkinsonian treatments for at least 1 month prior to inclusion in the study ;
  6. Patient with social health insurance ;
  7. Person who voluntarily and informedly agreed to participate in the study (signed written consent) ;
  8. Other medical problems that are stable or do not interfere with the proposed protocol;
Exclusion Criteria
  1. Parkinson's disease with Hoehn&Yahr stage 5 corresponding to an inability of the subject to stand or walk alone ;
  2. Dementia (MMS < 24 and/or MoCA < 18) ;
  3. Presence of an impulse control disorder defined by item 6 of the MDS-UPDRS part I > 2 ;
  4. Absence of internet connection at home ;
  5. Serious pathology interfering with the test ;
  6. Estimated life expectancy of less than 2 years ;
  7. Subject in a period of exclusion from further research ;
  8. Persons under guardianship, curatorship or any other administrative or judicial measure of deprivation of rights and liberty ;
  9. Pregnant woman or woman of childbearing age without contraceptive methods;

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
play-based rehabilitationplay-based rehabilitaionPatients randomized in the "play-based rehabilitation" group will perform 2 to 3 gambling rehabilitation sessions at home using the Kinect® system linked to the Curapy.com platform for 12 months.
Primary Outcome Measures
NameTimeMethod
The incremental cost-utility ratio at 12 months for the management of patients with Parkinson's disease using therapeutic gamesat 12 months for the management of patients with Parkinson's disease using therapeutic games

The result criterion is the additional cost in euros of a QALY gained. The QALY will be calculated from the utilities derived from the EuroQuality scale of life-5 dimensions EQ5D-3L.

Secondary Outcome Measures
NameTimeMethod
The level of physical activityThrough study completion, an average of 24 months

The level of physical activity evaluated with the International Physical Activity Questionnaire (IPAQ).

The frequency of fallsThrough study completion, an average of 24 months

The frequency of falls will be measured using item 12 of the Freezing of gait questionnaire (FOG-Q), with falls being absent (score=0), very rare (about 1/year, score=1), rare (about 1/ month, score=2), frequent (about 1/week, score=3) or very frequent (every day or several falls per day, score=4).

Cost-effectiveness ratio of falls preventionThrough study completion, an average of 24 months

For the cost-effectiveness ratio of falls prevention, the clinical outcome criterion will be measured by the number of falls at 12 and 24 months.

The budgetary impact of Toap RunThrough study completion, an average of 24 months

The budgetary impact of Toap Run in the management of Parkinson's patients will be measured by the resources directly consumed using the SNIIRAM/SNDS database (order of March 22, 2017 of the Public Health Code).

Patient and caregiver satisfactionThrough study completion, an average of 24 months

Patient and caregiver satisfaction will be assessed through a satisfaction survey.

Physician user satisfactionThrough study completion, an average of 24 months

Physician user satisfaction will be assessed through a satisfaction survey.

Incidence of treatment on Neurological motor skillsThrough study completion, an average of 24 months

Neurological motor skills will be assessed using a neurophysiological evaluation (VICON® System).

The incremental cost-effectiveness ratio of Toap Run therapeutic gambling management compared to usual management.Through study completion, an average of 24 months

The outcome criterion will be measured by the number of days of hospitalization at 12 and 24 months.

Incidence of treatment on Motor skillsThrough study completion, an average of 24 months

Motor skills (walking and balance) will be assessed using clinically validated scales (UPDRS, Gait and Balance Scale, Freezing-of-gait questionnaire, Fear of falling)

Incidence of treatment on Patients' quality of lifeThrough study completion, an average of 24 months

Patients' quality of life will be assessed using the PDQ-39 scale, which is specific to Parkinson's disease.

Mood and anxietyThrough study completion, an average of 24 months

Mood and anxiety will be assessed with the Hospital Anxiety Depression scale (HAD).

Criterion for the cost-utility ratioThrough study completion, an average of 24 months

The criterion for the cost-utility ratio at 24 months will be the QALY calculated from the utilities derived from the EuroQuality scale of life-5 dimensions EQ5D-3L.

Overall functioningThrough study completion, an average of 24 months

Overall functioning will be assessed by the Global Functioning Scale (GFS).

Evaluation of usability and feasibility of SGsThrough study completion, an average of 24 months

The usability and feasibility of SGs will be assessed through by patients' usability and feasability questionnaire.

Emotional stateThrough study completion, an average of 24 months

Emotional state will be assessed with the Positive Affect Negative Affect Scale (PANAS).

Trial Locations

Locations (1)

Rouen University Hospital

🇫🇷

Rouen, France

© Copyright 2025. All Rights Reserved by MedPath